Implantable particles for urinary incontinence

ABSTRACT

The invention encompasses the treatment of urinary incontinence, gastroesophageal reflux disease and the amelioration of skin wrinkles using biocompatible hydrophilic cationic microparticles and a cell adhesion promoter.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of co-pending application Ser. No.60/077,166, filed Mar. 6, 1998.

1. FIELD OF INVENTION

The present invention relates to tissue bulking, the treatmentgastroesophageal reflux disease, urinary incontinence and theamelioration of skin wrinkles.

2. BACKGROUND OF INVENTION 2.1 Gastroesophageal Reflux Disease (“GERD”)

Although gastroesophageal reflux is a normal physiological phenomenon,in some cases it is a pathophysiological situation that can result in avariety of symptoms which may become severe in extreme cases.Gastro-Esophageal Reflux Disease (“GERD”), describes a backflow ofacidic and enzymatic liquid from the stomach to the esophagus. It causesburning sensations behind the sternum that may be accompanied byregurgitation of gastric acid into the mouth or even the lung.Complications of GERD which define the severity of the disease includeesophageal tissue erosion, and esophageal ulcer wherein normalepithelium is replaced by a pathological tissue.

Statistical data indicate that about 35% of the American populationsuffer from heartburn at least once a month and between 5 to 10% once aday. More importantly for this kind of disease about 2% of the Americanpopulation suffer from GERD based on medical evidence data fromendoscopic examination. This disease is related to the age ofindividuals and seems to increase after 40 years of age. (Nebel O. T. etal., Am. J. Dig. Dis., 21(11):953-956 (1976)).

In normal patients, after a meal the lower esophageal sphincter remainsclosed, but in patients with GERD, it relaxes and allows some acidicmaterial to reflux into the esophageal tube as a result of stomachcontractions. Actually GERD can be attributed primarily to transientrelaxation of the lower esophageal sphincter. In other cases, GERD canbe attributed to decreased resting tone of the lower esophagealsphincter or to congenital small dimension of the sphincter itself.Other causes also exist which contribute to varying degrees to theexistence and severity of this disease.

In addition, there are external factors that contribute to exacerbatethe symptoms of GERD, which conditions include eating fatty foods,caffeine intake, smoking, tight clothing and certain medications.Decrease in salivation can also be a factor that exacerbates GERD, sinceunder normal conditions saliva, which is an alkaline liquid, aids inneutralizing acidic reflux and therefore diminishing the duration of theacidic exposure of the esophagus.

Erythema is one of the first visible signs of GERD, which can be seen byendoscopy. Tissue erosion indicates more advanced disease which can thenbecome deep ulcers and lead to cancer (adenocarcinoma increases inincidence faster than other types of cancer). Diffuse ulceration andspecific complications occur in about 3.5% of patients less than 65years of age with esophageal obstruction, blood loss, and in some cases,perforation. Ulcerative situations not only lead to complications, butthey are also more resistant to treatments. Although severecomplications are uncommon in young patients, they occur in about 20-30%of patients over 65 (Reynolds J. C, Am. J. Health-Sys. Pharm 53,(1996)).

Prior to the present invention, in an attempt to increase the functionof the sphincter, bulking methods using bovine collagen and Teflon pastehave been used in patients. Both methods have been unsuccessful,however, as these materials migrate over time from the initial site ofimplantation.

At present, GERD is generally managed by over-the-counter (“OTC”)antacids or prescription drugs, including proton pump inhibitors,motility agents and H₂ blockers. In addition, a portion of GERD patientsrequire surgical intervention; the most common type of surgery isfundoplication which can be done by conventional surgical techniques, orusing laparoscopic techniques. However, fundoplication surgery carriesthe risk of serious side effects and is only marginally successful incuring GERD. Respiratory symptoms are also associated with GERD in about50% of patients, and in patients undergoing fundoplication, theserespiratory symptoms can even increase (76% reported in a study byJohnson W. E. et al., Archives of Surgery, 131:489-492 (1996)).

2.2 Urinary Incontinence

Urinary incontinence is a prevalent problem that affects people of allages and levels of physical health, both in the community at large andin healthcare settings. Medically, urinary incontinence predisposes apatient to urinary tract infections, pressure ulcers, perineal rashes,and urosepsis. Socially and psychologically, urinary incontinence isassociated with embarrassment, social stigmatization, depression, andespecially for the elderly, an increased risk of institutionalization(Herzo et al., Ann. Rev. Gerontol. Geriatrics, 9:74 (1989)).Economically, the costs are astounding; in the United States alone, overten billion dollars per year is spent managing incontinence.

Incontinence can be attributed to genuine urinary stress (urethrahypermobility), to intrinsic sphincter deficiency (“ISD”), or both. Itis especially prevalent in women, and to a lesser extent incontinence ispresent in children (in particular, ISD), and in men following radicalprostatectomy.

One approach for treatment of urinary incontinence involvesadministration of drugs with bladder relaxant properties, withanticholinergic medications representing the mainstay of such drugs. Forexample, anticholinergics such as propantheline bromide, and combinationsmooth muscle relaxant/anticholinergics such as racemic oxybutynin anddicyclomin, have been used to treat urge incontinence. (See, e.g., A. J.Wein, Urol. Clin. N. Am., 22:557 (1995)). Often, however, such drugtherapies do not achieve complete success with all classes ofincontinent patients, and often results in the patient experiencingsignificant side effects.

Besides drug therapies, other options used by the skilled artisan priorto the present invention include the use of artificial sphincters (LimaS. V. C. et al., J. Urology, 156:622-624 (1996), Levesque P. E. et al.,J. Urology, 156:625-628 (1996)), bladder neck support prosthesis (KondoA. et al., J. Urology, 157:824-827 (1996)), injection of crosslinkedcollagen (Berman C. J. et al., J. Urology, 157:122-124 (1997), Perez L.M. et al., J. Urology, 156:633-636 (1996); Leonard M. P. et al., J.Urology, 156:637-640 (1996)), and injection of polytetrafluoroethylene(Perez L. M. et al., J. Urology, 156:633-636 (1996)).

A recent well known approach for the treatment of urinary incontinenceassociated with ISD is to subject the patient to periurethral endoscopiccollagen injections. This augments the bladder muscle in an effort toreduce the likelihood of bladder leakage or stress incontinence.

Existing solutions to circumvent incontinence have well known drawbacks.The use of artificial sphincters for children with intractableincontinence requires long term surveillance of the urinary tractbecause of the potential for renal failure after device placement(Levesque P. E. et al., J. Urology, 156:625-628 (1996)). Whileendoscopically directed injections of collagen around the bladder neckhas a quite high success rate in sphincter deficiency with nosignificant morbidity, the use of collagen can result in failures thatoccur after an average of two years and considerations need to be givento its cost effectiveness (Khullar V. et al., British J. Obstetrics &Gynecology, 104:96-99 (1996)). In addition, deterioration of patientcontinency, probably due to the migration phenomena (Perez L. M. et al.)may require repeated injections in order to restore continency(Herschorn S. et al., J. Urology, 156:1305-1309 (1996)).

The results with using collagen following radical prostatectomy for thetreatment of stress urinary incontinence have also been generallydisappointing (Klutke C. G. et al., J. Urology, 156:1703-1706 (1996)).Moreover, one study provides evidence that the injection of bovinedermal collagen produced specific antibodies of IgG and IgA class.(McCell and, M. and Delustro, F., J. Urology 155, 2068-2073 (1996)).Thus, possible patient sensitization to the collagen could be expectedover the time.

Despite of the limited success rate, transurethral collagen injectiontherapy remains an acceptable treatment for intrinsic sphincterdeficiency, due to the lack other suitable alternatives.

2.3 Skin Wrinkles

Damage to the skin due to aging or exposure to the sun and otherelements often results in wrinkles and other skin anomalies. In order toremove wrinkles from the skin, people often resort to cosmetic surgery,such as face lifts and skin tucks. In addition, collagen injections havebeen used to remove or ameliorate skin wrinkles. Collagen injectionshave also been used for tissue bulking or to increase the fullness ofcertain body parts, e.g., to increase the fullness of lips or around theeyes and eyebrow area of the face. However, collagen is a naturallyoccurring substance which the body may enzymatically degrade andeliminate over time, thus requiring repeat treatments. Even morealarming from a cosmetic perspective, collagen may move from the initialsite of injection, causing unsightly bumps and bulges under the skin atundesired locations.

Microbeads or solid microparticles have been used for the correction ofskin wrinkles. For examples, silicone particles, TEFLON paste, collagenbeads and polyacrylic microspheres have been used with disappointingresults due to, inter alia, adverse tissue reactions, biologicaldegradation and migration from the initial implantation location.

2.4 MicroParticles

Prior to the present invention, microspheres have been manufactured andmarketed for in vitro use in anchorage dependent cell culture. (VanVezel, A. L., Nature, 216:64-65 (1967); Levine et al., Somatic CellGenetics, 3:149-155 (1977); Obrenovitch et al., Biol. Cell., 46:249-256(1983)). They have also been used in vivo to occlude blood vessels inthe treatment of arteriovascular malformation, fistulas and tumors (See,U.S. Pat. No. 5,635,215, issued Jun. 3, 1997 to Boschetti et al.;Laurent et al., J. Am. Soc. Neuroiol, 17:533-540 (1996); and Beaujeux etal. J. Am. Soc. Neuroial, A:533-540 (1996)).

Further, direct implantation of cells into living tissues such as brainor liver to correct specific deficiencies has been attempted albeit witha number of failures. The major problems associated with direct celltransplantation are the long term viability of the cell transplant andthe immunopathological as well as histological responses. Microparticleswith cells attached on their surface have been used in some in vivoapplications. Cherkesey et al., IBRO, 657-664 (1996), described theculture of adrenal cells on coated dextran beads and the implantationinto mammalian brain to supplant some specific disorders related to6-hydroxydopamine-induced unilateral lesions of the substantia nigra.The pre-attachment of cells to dextran microcarriers allowed forimproved functions of the cells implanted into the brain. Also livercells transplantation has been used to manage acute liver failure, orfor the replacement of specific deficient functions such as conjugationof bilirubin or synthesis of albumin. For this purpose, an intrasplenicinjection of hepatocytes grown on the surface of microspheres wasperformed (Roy Chowdhury et al., in: Advanced Research on Animal CellTechnology, AOA Miller ed., 315-327, Kluers Acad. Press, 1989).

Most of cell implant results have been, however, largely disappointingfor the designated functions (or have had low levels of biologicalfunction).

3. SUMMARY OF INVENTION

The present invention encompasses the use of implantable microparticlesin the treatment of GERD, urinary incontinence and skin wrinkles. Ineach use the particles are implanted into the appropriate tissue,muscle, organ etc. as a bulking agent. Further, in each use themicroparticles are preferably pre-coated, with autologous cells, forexample, muscle cells, fat cells and the like. The microparticles of theinvention are biocompatible non-toxic polymers coated with, linked to orfilled with cell adhesion promoters. The microparticles preferablycontain a positive charge on their surface by way of a cationic monomeror polymer.

In one embodiment, the invention encompasses the treatment ofgastroesophageal reflux disease in a human which comprises implantinghydrophilic biocompatible microparticles comprising (a) a positivecharge and a cell adhesion promoter; and (b) autologous cells layered onthe surface of said beads, into the lower esophageal sphincter. Themicroparticles are preferably microspheres or microbeads which aredescribed in detail herein. The autologous cells are preferably takenfrom the area where the implantation is to be made. Serum or whole bloodtaken from the patient can be used to wash the microparticles prior toimplantation. For GERD treatment implantation may also be made by usingstandard techniques known to the skilled artisan, such as injection (orinjections) via syringe or other suitable devices.

In yet another embodiment, the invention encompasses the treatment ofurinary incontinence in a human which comprises implanting hydrophilicbiocompatible microparticles comprising (a) a positive charge and a celladhesion promoter; and (b) autologous cells layered on the surface ofthe beads, into the urinary sphincter. The microparticles are preferablymicrospheres or microbeads as described herein. Further, the autologouscells are preferably taken from the area where the implantation is to bemade. Serum or whole blood from the patient can be used to wash themicroparticles prior to implantation. Implantation is generally madeusing a syringe or other device suitable for the particular tissue ofimplantation.

In another embodiment, the invention encompasses a method of treatingskin wrinkles in a human which comprises the administration orimplantation of microparticles comprising a hydrophilic copolymer havinga positive charge, and a cell adhesion promoter, which microparticleshave been pre-treated with autologous cells. The microparticles can besimply exposed to the autologous cells or mixed thoroughly withautologous cells prior to implantation.

It should be recognized that both treatments for GERD and urinaryincontinence described above can be used in combination withconventional therapies now used to treat these diseases i.e., oraldiuretics, antacids, suitable drug therapy and the like. Suchcombination therapy can lead to a faster, safer and more comfortablerecovery for the patient.

In yet another embodiment, the invention encompasses the treatment oramelioration of skin wrinkles which comprises administering hydrophilicbiocompatible microparticles comprising: (a) a positive charge and acell adhesion promoter; and (b) autologous cells, collagen, collagenderivatives or glucosaminoglycans layered on the surface of the beads,into the area of or surrounding the skin wrinkles. In other words,microspheres or microbeads coated with a cell adhesion promoter andpre-treated with the appropriate tissue bulking cells, are administeredto the area of treatment.

As used herein the terms “administered”, “implanted”, or “implantation”are used interchangeably and mean that the material is delivered to thearea of treatment by techniques know to those skilled in the art andappropriate for the disease to be treated. Both invasive andnon-invasive methods may be used for delivery.

4. BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic representation of sphincter bulking. Beads arecoated and injected under physiological conditions into the sphincter.The sphincter volume increases proportionally to the amount of injectedbeads and the lumen size decreases. The beads are progressively andnon-reversibly integrated within the muscles.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention uses microparticles, particularly microbeads,having a positive charge on its surface and a cell adhesion promoter andoptionally, a cell growth promoting agent, to treat GERD, urinaryincontinence, and skin wrinkles. The microparticles of the invention arepreferably used with autologous cells. In other words, themicroparticles of the invention are colonized with the appropriate cellsprior to implantation. This pre-implantation step has been shown toreduce or eliminate immunological responses and implantation rejectionreactions. Further, the use of non-biodegradable biologically compatiblemicrobeads with positive charges and autologous cells, whethertissue-specific or not, improves tissue acceptance and overalltreatment.

According to the methods of the present invention, treatment of GERD,urinary incontinence, and skin wrinkles is achievable while avoiding orsubstantially reducing adverse tissue reactions, including implantationrejection, degradation of particles, resorption, migration and otheradverse events. The methods of the invention also involve increasedconnective tissue response.

Microbeads or microparticles for use in the present invention are basedon a biocompatible non-toxic polymer coated with agents which promotecell adhesion. Living cells attach to the microparticles forming layeredcells therein which link with surrounding tissues to enhance long termstability of the beads.

Microparticles intended to be implanted in various locations of the bodyaccording to the present invention are composed of a non-resorbablehydrophilic polymer containing the appropriate material for celladhesion, and may additionally contain radiopaque molecules or othermarking agents, to facilitate localization by radiology prior to orduring intervention. Hydrophilic copolymers usable for this applicationare those of the acrylic family such as polyacrylamides and theirderivatives, polyacrylates and their derivatives as well as polyallyland polyvinyl compounds. All of these polymers are crosslinked so as tobe stable and non-resorbable, and can contain within their structureother chemicals displaying particular properties, such as chemotacticeffects, promotion of cell adhesion to cells or tissues, such as cellsof the esophagus wall or the urethra wall, or skin cells, and/or markingagents.

The microparticles for use in the present invention are non-toxic totissues and cells, biocompatible, and adhesive to various cells andtissues at the site of implantation by means of the cell growth theypromote. In addition, these microparticles are non-resorbable andnon-biodegradable, and thus are stable, durable, and will maintain theirgeneral shape and position once implanted at a desired site.

In general, microparticles for use in the present invention may have anyshape, with microparticles which are spherical in shape being preferred.Microparticles for use in the present invention may have diametersranging between about 10 μm to about 1000 μm. Preferably, microparticlesfor use in the present invention which have cells adhered to the surfacethereof will have diameters ranging between 50 μm and 1000 μm.

Possible variations of the present invention include replacing themicroparticles with any biocompatible, nontoxic non-resorbable polymericparticles, membrane, fibers or other solid substrates treated with anagent promoting cell adhesion. The invention also includes linearsoluble polymers which, after injection, crosslink in situ to constitutea solid, cell adhesion promoting filling agent. Preparation and/orinjection of empty microparticles (microbubbles) that are prepared inadvance or are generated in place via the use of appropriate catheters,are also contemplated in this invention.

The microparticles, or other solid substrates, for use in the presentinvention are flexible, such that they can easily pass into and throughinjection devices and small catheters without being permanently altered,but the microparticles are also resistant to the muscle contractionstress generated during and after the implantation process. They arealso thermally stable which allows for easy, convenient sterilization,and frozen storage.

The microparticles, or other solid substrates, for use in the presentinvention are also stable in suspension which allows the microparticlesor other solid substrates to be formulated and stored in suspension andinjected with different liquids. More specifically, the hydrophilicnature of the microparticles permits placing them in suspension, and inparticular, in the form of sterile and pyrogenic (pyrogen-free)injectable solutions, while avoiding the formation of aggregates oradhesion to the walls of storage containers and implantation devices,such as catheters, syringes, needles, and the like. Preferably, theseinjectable solutions contain microparticles or other solid substratesdistributed approximately in caliber segments ranging between about 10μm and about 2000 μm.

The microparticles of the present invention are both hydrophilic andcationic. The microparticles preferably comprise a copolymer of aneutral hydrophilic monomer, a difunctional monomer, one or moremonomers having a cationic charge, and optionally, a functionalizedmonomer capable of rendering the microparticle detectable. Themicroparticles may also comprise one or more cell adhesion promoters anda marking agent.

The copolymer is preferably a hydrophilic acrylic copolymer whichcomprises in copolymerized form about 25 to about 98% neutralhydrophilic acrylic monomer by weight, about 2 to about 50% difunctionalmonomer by weight and about 0 to about 50% by weight of one or moremonomers having a cationic charge.

By way of example, the copolymers described in French Patent 2,378,808,which is incorporated herein by reference, can be used in accordancewith this invention to prepare the base microparticle copolymer.

As hydrophilic acrylic monomer, acrylamide and its derivatives,methacrylamide and its derivatives or hydroxymethylmethacrylate can beused.

Examples of difunctional monomer, include but are not limited to theN,N′-methylene-bis-acrylamide, N′,N′-diallyltartiamide orglyoxal-bis-acrylamide.

Further, the monomer having a cationic charge, includes but is notlimited to those carrying a tertiary or quaternary amine function,preferably diethylaminoethyl acrylamide, methacrylamidopropyltrimethylammonium or acrylamidoethyl triethylammonium.

In a particularly preferred embodiment, a copolymer comprising about 25to about 98% methacrylamide by weight, about 2 to about 50%N,N-methylene-bis-acrylamide by weight is used.

In one particularly advantageous embodiment of the invention, it ispossible to increase the stability of the microspheres by reticulatingthe adhesion agent. By way of example, in the case of gelatin, thereticulating agent can be chosen among the difunctional chemical agentsreacting on the gelatin amines (e.g., glutaraldehyde, formaldehyde,glyoxal, and the like).

The functionalized monomer is generally obtained by chemical coupling ofthe monomer with a marker, which can be:

a chemical dye, such as Cibacron Blue or Procion Red HE-3B, makingpossible a direct visualization of the microspheres (Boschetti, J.Biochem-Biophys. Meth., 19:21-36 (1989)). Examples of functionalizedmonomer usable for this type of marking N-acryloyl hexamethyleneCibacrone Blue or N-acryloyl hexamethylene Procion Red HE-3B;

a magnetic resonance imaging agent (erbium, gadolinium or magnetite);

a contrasting agent, such as barium or iodine salts, including forexample acylamino-e-propion-amido)-3-triiodo-2, 4, 6-benzoic acid, whichcan be prepared under the conditions described by Boschetti et al.(Bull. Soc. Chim., No. 4 France, (1986)). In the case of barium ormagnetite salts, they can be directly introduced in powered form in theinitial monomer solution.

As indicated above it is also possible to mark the microspheres aftertheir synthesis. This can be done, for example, by grafting offluorescent markers derivatives (including for example fluoresceinisothiocyanate (FITC), rhodamine isothiocyanate (RITC) and the like).

Various types of cell adhesion promoters well known in the art may beused in the present invention. In particular, cell adhesion promoterscan be selected from collagen, gelatin, glucosaminoglycans,fibronectins, lectins, polycations (such polylysine, chitosan and thelike), or any other natural or synthetic biological cell adhesion agent.

Preferably, the cell adhesion promoter is present in the microparticle,or other solid substrate, in an amount between about 0.1 to 1 g per mlof settled microparticles.

Microparticles are prepared by suspension polymerization, drop-by-droppolymerization or any other method known to the skilled artisan. Themode of microparticle preparation selected will usually depend upon thedesired characteristics, such as microparticle diameter and chemicalcomposition, for the resulting microparticles. The microparticles of thepresent invention can be made by standard methods of polymerizationdescribed in the art (see, e.g., E. Boschetti, Microspheres forBiochromatography and Biomedical Applications. Part I, Preparation ofMicrobands In: Microspheres, Microencapsulation and Liposomes, JohnWiley & Sons, Arshady R., Ed., 1998 (in press) which is incorporatedherein by reference). Microspheres are prepared starting from an aqueoussolution of monomers containing adhesion agents such as collagen(gelatin is a denatured collagen). The solution is then mixed with anon-aqueous-compatible solvent to create a suspension of droplets, whichare then turned into solid gel by polymerization of monomers by means ofappropriate catalysts. Microspheres are then collected by filtration orcentrifugation and washed.

Cell adhesion promoters or marking agents are introduced on microbeadsby chemical coupling procedures well known in affinity chromatography,referred to by the term “ligand immobilization”. Another method ofintroduction is by diffusion within the gel network that constitutes thebead and then trapping the diffused molecules in place by precipitationor chemical cross-linking. Therapeutic agents, drugs or any other activemolecules that are suitable for transportation by the beads can also beintroduced into the microbeads prior to bead implantation according tothis last method.

The microspheres of the invention can also be obtained by standardmethods of polymerization described in the art such as French Patent2,378,808 and U.S. Pat. No. 5,648,100, each of which is incorporatedherein by reference. In general, the polymerization of monomers insolution is carried out at a temperature ranging between about 0° C. andabout 100° C. and between about 40° C. and about 60° C., in the presenceof a polymerization reaction initiator.

The polymerization initiator is advantageously chosen among the redoxsystems. Notably, it is possible to use combinations of an alkali metalpersulfate with N,N,N′,N′-tetramethylethylenediamine or withdimethylaminopropionitrile, organic peroxides such as benzoyl peroxidesor even 2,2′-azo-bis-isobutyronitrile.

The quantity of initiator used is adapted by one skilled in the art tothe quantity of monomers and the rate of polymerization sought.

Polymerization can be carried out in mass or in emulsion.

In the case of a mass polymerization, the aqueous solution containingthe different dissolved constituents and the initiator undergoespolymerization in an homogeneous medium. This makes it possible toaccess a lump of aqueous gel which can then be separated intomicrospheres, by passing, for example, through the mesh of a screen.

Emulsion or suspension polymerization is the preferred method ofpreparation, since it makes it possible to access directly microspheresof a desired size. It can be conducted as follows: The aqueous solutioncontaining the different dissolved constituents (e.g., differentmonomers, cell adhesion agent), is mixed by stirring, with a liquidorganic phase which is not miscible in water, and optionally in thepresence of an emulsifier. The rate of stirring is adjusted so as toobtain an aqueous phase emulsion in the organic phase forming drops ofdesired diameter. Polymerization is then started off by addition of theinitiator. It is accompanied by an exothermic reaction and itsdevelopment can then be followed by measuring the temperature of thereaction medium.

It is possible to use as organic phase vegetable or mineral oils,certain petroleum distillation products, chlorinated hydrocarbons or amixture of these different solutions. Furthermore, when thepolymerization initiator includes several components (redox system), itis possible to add one of them in the aqueous phase beforeemulsification.

The microspheres thus obtained can then be recovered by cooling,decanting and filtration. They are then separated by size category andwashed to eliminate any trace of secondary product.

The polymerization stage can be followed by a stage of reticulation ofthe cell adhesion agent and possibly by a marking agent stage in thecase of microspheres rendered identifiable by grafting after synthesis.

Microparticles of the present invention which have the specificproperties of cell adhesion and growth promotion can be used directlyfor tissue bulking. Moreover, the microparticles of the presentinvention can have specific autologous cells grown on their surface invitro, thereby making the microparticles particularly useful for tissuebulking.

Prior to the present invention, the injection of implantable substancessuspended in a physiological solution into a tissue resulted in theformation of discrete aggregates inside the muscle mass. These discreteaggregates can constitute various amounts of the implanted substancewhich stays together, however, the substance does not become attached toor a part of the tissue itself. This detachment allows the implantedsubstance to move from the original implantation site.

According to the present invention, in order to avoid this problem, themicroparticles may be injected individually and separately, or morepreferably, the surface of the microparticles may be colonized by alayer of cells for better integration and long term stability of theimplant.

Microparticles of the present invention demonstrate superior ability togrow cells on their surfaces. For example, primary muscle cells havebeen successfully adhered to the surface of the microparticles of thepresent invention thereby allowing for a better integration within amuscle tissue. In addition, since the ultimate goal of tissue bulking isto artificially increase tissue mass, preadipocytes have also been usedto colonize the surface of the microparticles prior injection. In thiscase, the preadipocytes have a volume similar to any other regular cell,but after implantation when the preadipocytes are subject to in vivophysiological conditions, they accumulate droplets of fats therebyincreasing the mass of the implant by more than 10% in volume.

According to the present invention, one means of performing tissuebulking in a patient can be described as follows:

a) Primary cells are extracted from the patient by a simple biopsy andisolated;

b) These cells are grown on the surface of the microparticles undergrowth promoting conditions (e.g., possibly using a nutrient media whichcontains autologous serum (drawn from the patient), until confluence);

c) the microparticles having the patient's cells grown on the top areinjected into the patient's target tissue to be bulked.

For the treatment of GERD, the microparticles, or other solidsubstrates, are introduced via the esophagus, either by endoscopicdelivery or by laparoscopic technique, and are injected into the wallsof the sphincter where the esophagus meets the stomach, i.e., the loweresophageal sphincter. This decreases the internal lumen of the sphinctermuscle thus permitting easier contraction of the muscle with reducedregurgitation of the gastric fluids into the esophagus. In addition,this treatment reduces the inflammation of the lower esophagus. Themicroparticles, or other solid substrates, may also be loaded with X-rayopaque dye or other imaging agents for subsequent X-ray visualization.

In another embodiment, microparticles injected into the sphincter at thejunction of the esophagus and stomach in order to treat GERD may alsoinclude an amount of a drug used to treat GERD, such as H₂ histamineantagonists including cimetidine, ranitidine, famotidine and nizatidine;inhibitors of H⁺, K⁺-ATPase including omeprazole and lansoprazole;antacids including e.g., Al(OH)₃, Mg(OH)₂, and CaCO₃. As with thetreatment of urinary incontinence and skin wrinkles, the microspheresmay also be used with anti-inflammatory agents, angiogenesis inhibitors,radioactive elements, and antimitotic agents.

Other therapeutic agents to be used in combination with the microspheresor microparticles of the present invention include those for thetreatment of skin disorders, GERD and urinary incontinence as reportedin Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9thEd., McGraw-Hill (1996) and The Physicians's Desk Reference® 1997.

The primary advantages of the method of treating GERD according to thepresent invention over the prior art methods are:

a) Less invasive effects on the patient compared to surgery;

b) More permanent effects over antacids or other drugs;

c) Good biocompatibility with chemotactic effects; and

d) Ability to use X-ray visualization or MRI to assist in follow-upevaluation of the patient.

For the treatment of urinary incontinence, the microparticles, or othersolid substrates, are introduced via the urethra and injected into thewalls of the bladder sphincter, decreasing the internal lumen of thesphincter muscle thus permitting easier contraction of the muscle withreduced likelihood of incontinence. The microparticles, or other solidsubstrate, may also be loaded with X-ray opaque dye, or other imagingagents for subsequent X-ray visualization.

In another embodiment, microparticles injected into the bladdersphincter in order to treat urinary incontinence may also include anamount of a drug used to treat urinary incontinence, such asantidiuretics, anticholinergics, oxybutynin and vasopressins.

Injected microparticles can generate some transient adverse reactionssuch as local inflammation, therefore the microparticles can contain orbe injected with anti-inflammatory drugs, such as salicylic acidderivatives including aspirin; para-aminophenol derivatives includingacetaminophen; non-steroidal anti-inflammatory agents includingindomethacin, sulindac, etodolac, tolmetin, diclodfenac, ketorolac,ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin;anthranilic acids including mefenamic acid, meclofenamic acid; enolicacids such as piroxicam, tenoxicam, phenylbutazone, oxyphenthatrarone;and nabumetone. These anti-inflammatories are preferably adsorbed on themicroparticle's network and released slowly over a short period of time(a few days). The microparticles may also be used to release otherspecific drugs which can be incorporated within the microparticlenetwork before injection into the patient. The drug would be releasedlocally at the site of implantation over a short period of time toimprove the overall treatment.

Incorporation of active molecules, such as drugs, into themicroparticles of the present invention can be accomplished by mixingdry microparticles with solutions of said active molecules or drugs inan aqueous or hydro-organic solution. The microparticles swell byadsorbing the solutions and incorporate the active molecule of interestinto the microparticle network. The active molecules will remain insidethe microparticle due to an active mechanism of adsorption essentiallybased on ion exchange effect. The microparticles by their nature carrycationic groups and have the ability to adsorb anionic molecules, suchas well known anti-inflammatory drugs, and these anionic molecules arethen released slowly upon injection into the patient due to the actionof physiological salt and pH. The ability of various types ofmicroparticles to adsorb drug molecules may be readily determined by theskilled artisan, and is dependent on the amount of cationic monomerspresent in the initial solution from which the microparticles areprepared.

Some of the primary advantages of treating urinary incontinenceaccording to the present invention over prior art methods are:

a) More permanent effect than the use of regular viscous solutions ofcollagen;

b) Good biocompatibility with chemotactic effect;

c) Visualization under X-ray or MRI to assist in follow-up evaluation;and

d) Preventing repeated treatments with resorbable naturally occurringsubstances like collagen.

The primary advantages of the method of treating skin wrinkles accordingto the present invention are:

(a) less invasive effects on the patient compared to surgery;

(b) more permanent effects than the use of collagen injections; and

(c) good biocompatibility with chemotactic effects.

For treatment of skin wrinkles, the microparticles may be introduced viainjection. The microparticles may also include one or moreanti-inflammatory agents.

The invention is further defined by reference to the following examplesthat describe in detail the preparation of microparticles for use intissue bulking, and the treatment of skin wrinkles, urinaryincontinence, and GERD. The following examples are illustrative only andshould in no way limit the scope of the present invention. It will beapparent to those skilled in the art that many modifications, both tomaterials and methods, may be practiced without departing from thepurpose and scope of this invention.

6. EXAMPLES 6.1 Example 1 Preparation of Irregular Hydrogel Particleswith Chemotactic Properties

58 grams of sodium chloride and 27 grams of sodium acetate weredissolved at room temperature in 100 ml of demineralized water. To thissolution 400 ml of glycerol were added, the pH was adjusted to 6.0 andmonomers were then dissolved. More specifically to this solution 90 gramof methylolacrylamide, 2 g ofmethacrylamidopropyl-trimethyl-ammonium-chloride hydrochloride and 10gram of N,N′-methylene-bis-acrylamide were added and the mixture wasagitated until complete solubilization. The solution was heated at about70° C. and 100 ml of a solution of gelatin at a concentration of 500mg/ml was added. The total volume of the mixture was then adjusted to1000 ml by addition of demineralized water. Finally 20 ml of 70 mg/mlammonium persulfate aqueous solution and 4 ml ofN,N,N′,N′-tetramethyl-ethylene-diamine was added. The obtained mixturewas stored at 70° C. for about 3 hours until formation of a compactthree-dimensional gel. This gel was totally insoluble in water. It wascut in small pieces and then ground to get very small particles of adimension close to 100-200 μm. The particles were then suspended in 1liter of physiological buffer containing 5% (w/v) glutaraldehyde andwere shaken for two hours. Finally the particles were extensively washedto eliminate unpolymerized material, by-products and salts. To obtainhomogeneous particle size distribution the particle suspension wassieved using an appropriate sieving net.

These particles possess the characteristics desired for tissue celladhesion prior to muscle bulking and include cationic groups andadhesion agents for an effective cell adhesion mechanism.

6.2 Example 2 Preparation of Spherical Polyacrylic Hydrogel GelParticles with Chemotactic Properties

The solution of monomers prepared as described in Example 1 above waspoured slowly into 1500 ml of stirred and hot paraffin oil (50-70° C.).After a few minutes a suspension/emulsion of liquids was obtained (theaqueous monomer solution was dispersed into oil and forms very smallspherical droplets) and the polymerization occurred in suspension. Themicrodroplets were transformed into microbeads. The solid microbeadswere recovered by centrifugation and suspended in 1 liter ofphysiological buffer containing 5% (w/v) glutaraldehyde and shaken fortwo hours. Finally the particles were extensively washed with water toeliminate completely the oil traces. Organic solvent extraction can beused for a more effective oil removal or an extensive washing in thepresence of traces of nonionic detergents. The obtained microbeads arecalibrated if necessary by sieving through a nylon net and sterilized inan autoclave. These microspheres possess desired characteristics andproperties for cell adhesion prior to muscle bulking.

6.3 Example 3 Preparation of Hydrophilic Spherical Polystyrene CopolymerParticles Useful for Tissue Bulking

10 gram of styrene is mixed with 60 ml of toluene. 1 gram ofdivinylbenzene, 1 gram of dimethyl-aminoethyl-methacrylate and 1 gram ofdimethyl-acrylamide are added to the resulting solution. After completesolubilization the monomer solution is mixed with 1% of AIBN(2,2′-azobisisobutyronitrile) as a polymerization catalyst and with 40ml of paraffin oil as a viscosity inducer agent. The mixture is pouredin an agitated water solution containing 0.5% Tween 80. In thissituation there is formation of droplet suspension which turns intosolid microbeads when the temperature is raised to 80-90° C. for threeto five hours. The resulting beads are dried and organic solventsextracted. They are then swollen in an aqueous solution of collagen inphosphate buffer at neutral pH. Embedded collagen is then crosslinkedwith glutaraldehyde as described in Examples 1 and 2. The resultingbeads possess cationic charges to interact with cell tissues andcollagen for cell adhesion, and a chemotactic agent for cell growth andbiocompatibility. They are suitable as tissue bulking agent.

6.4 Example 4 Preparation of Hydrophilic Silicone Beads for CellAdhesion and Tissue Bulking

10 gram of silicone beads of a diameter of 20-300 μm are suspended in 30ml of a solution of hexadecylamine (10 mg/ml) in ethylacetate. Thesuspension is stirred for two hours and 100 ml of ethanol is added. A 1M ammonium sulfate or sodium chloride solution in water is added slowlyuntil a 300 ml suspension is obtained. The amino-containing siliconebeads are then reacted with a butanedioldiglycydylether in alkalineconditions. Epoxy derivatives are thus obtained on which gelatin iscoupled using a method well known in the art. The resulting beads havethe target properties of biocompatibility, hydrophilicity,non-biodegradability and cell adhesion by the presence of cationic aminogroups and of gelatin as a cell growth promoting agent. They aresuitable for tissue bulking in accordance with the present invention.

6.5 Example 5 Preparation of Beads for Tissue Bulking ContainingAdhesion Factors

Beads prepared according to Example 2 were chemically activated withwell known reagents used in the preparation of affinity chromatographysorbents. Activated beads were then used for the immobilization of celladhesion agents such as fibronectin or vitronectin or laminin. Adhesionagents were dissolved at 1-10 mg/ml in a coupling buffer (100 mMcarbonate or borate buffer pH 8 to 10) and the solution was mixed withthe activated beads. The resulting beads possess the target propertiesof cell adhesion and growth, non-biodegradability and werenon-resorbable. They are suitable for cell adhesion and permanent tissuebulking in accordance with the present invention. Similarly, beadsprepared according to Examples 3 and 4 can also be used.

6.6 Example 6 Preparation of Spherical Polyacrylic Hydrogel Particleswith Chemotactic Properties

Microbeads commercially available under the name SPEC-70 (BioSepra Inc.,Marlborough, Mass.) are polyacrylic polyanionic beads with elasticproperties suitable for tissue bulking applications. However, thesemicrobeads are not chemotactic and do not possess cationic charges.SPEC-70 microbeads are first drained under vacuum to eliminate water andthen suspended in an aqueous solution of 1% chondroitin sulfate sodiumsalt in physiological conditions. Once this compound is absorbed on thebead structure, the beads are drained under vacuum and suspended in anaqueous solution containing 20% polylysine by weight. The suspension isshaken for a few hours and then drained under vacuum and rapidly washedwith distilled water. The beads are then suspended in a solution of 5%butanedioldiglycidylether in ethanol and shaken overnight. Under theseconditions, the polylysine is crosslinked as well as chondroitinsulfate. The resulting modified beads possess properties such ascationic charge for cell adhesion and promoting agents for cell growthsuch as polylysine and chondroitin sulfate.

6.7 Example 7 Preparation of Radiopaque Microbeads with ChemotacticProperties for Tissue Bulking

Microbeads from Examples 2 were drained under vacuum and then suspendedin a saturated solution of barium chloride. They were shaken for twohours at room temperature and then drained under vacuum to eliminate theexcess of barium chloride solution. The beads were suspended in asaturated solution of ammonium sulfate and shaken for two additionalhours before elimination of the excess ammonium sulfate by vacuumfiltration. This operation of contact with barium salts and ammoniumsulfate can be repeated several times until the resulting radiopaqueprecipitate inside the beads reaches the desired amount. Resulting beadshave radiopaque properties without having lost their initial desirableproperties for tissue bulking. The microbeads from Examples 3, 4 and 6can be similarly used.

6.8 Example 8 Preparation of Radiopaque Microbeads with ChemotacticProperties for Tissue Bulking

Microbeads from Example 6 coated with polylysine are washed extensivelywith distilled water and suspended in a solution of sodium triazoate.The suspension pH is adjusted at about 7 by addition of acetic acid andshaken for several hours. The triazoate which is a radiopaque moleculeis adsorbed tightly to the beads and the remaining reagents areeliminated by washing under vacuum. The resulting beads still possesscell promotion properties and now radiopacity as well.

6.9 Example 9 Introduction of Anti-inflammatory Drugs Inside the BulkingBeads

Microbeads described in the previous Examples may generate localtemporary inflammatory reactions when injected in the target tissue. Toavoid or decrease this phenomenon, the microbeads once coated withautologous cells can be filled with one or more anti-inflammatory drugs.The microbeads are cationic by their nature and can absorb anionic drugsby ion exchange effect.

Prior to injection microbeads are mixed with a 10 mg/mlanti-inflammatory anionic drug solution in sterile physiological saline.The suspension is shaken for several hours, and the beads filled withthe drug are recovered by filtration or centrifugation. The resultinganti-inflammatory containing microbeads may then be used as tissuebulking agents for use in the present invention.

6.10 Example 10 In Vitro Pre-adipocytes Adhesion and Growth on PolymericBeads

In order to assess the ability of polymeric beads from Example 2 toallow adhesion and growth of pre-adipocytes, fresh pre-adipocytes werecollected and isolated from Wistar rat peri-epididymal fat tissue.Pre-adipocytes were then cultured in the presence of above describedmicrobeads at a concentration of about 7.1×10⁵ to about 1.7×10⁶ cells/mlusing the classical protocol for microcarrier culture in vitro. In afirst phase the cells adhere on the bead surface and then they grow tototally cover the bead surface. The total colonization period is about72 hours.

Pre-adipocytes from this type of culture show good growth and specificbiological activity associated with differentiation into adipocytes(accumulation of lipids). Moreover these cells show the presence ofspecific enzymatic markers such as glycerol-3-phosphate-dehydrogenaseand malate dehydrogenase. Microbeads having cells adhered thereto areuseful for tissue bulking for use in the present invention. Thepolymeric beads of Examples 2 to 5 can be similarly assessed.

6.11 Example 11 Culture of Pre-adipocytes and Myocytes on Microbeads InVitro to Check Their Ability of Integrate Into an In Vivo Tissue

Preadipocytes and smooth muscle cells were isolated from Wistar ratsaccording to a classical protocol to eliminate most of othercontaminating cells. Separately these cells were cultured in a Petridish in the presence of Dulbecco's Modified Eagle Medium supplementedwith 10% fetal bovine serum. Gelatin-coated cationic microbeads preparedin accordance with Example 2 were added to cells cultured in vitro untilthey covered the surface of the Petri dish. Initial cell seedconcentration was 0.7×10⁶ cells/ml.

Repeated observations showed that cells adhered on the surface ofmicrobeads and further multiplied to cover all the surface of the beads.After 5 to 7 days of culturing, there was formation of a solid networkof beads where cells acted as a binder to consolidate the blocks ofseveral beads. In most cases there were formation of solid nondissociable aggregates comprising beads and cells.

When, after a growing period (generally 5 to 7 days), a differentiatingelement such as 3,3′,5-triiodo-D-thyronine was added to preadipocytes,the preadipocytes started to accumulate fats as micro-droplets withinthe cytoplasm.

Specific staining with 3,3′-dioctadecyloxacarbocyanine perchlorate or2′-[4-hydroxyphenyl]-5-[4-methyl-1-piperazinyl]2,5′-bi-1H-benzimidazoledemonstrated good adhesion of the cells on the bead substrate.

Staining of the cells with red oil at the beginning of thedifferentiating phase evidenced the accumulation of fats inside thecells.

In addition, specific enzymatic reactions of malic enzyme indicatedthat, at the end of the culture, resulting adipocytes were functionallyviable with their major expressed characteristics. This enzyme is notexpressed at the beginning of the culture and appeared simultaneouslywith the accumulation of fats.

Smooth muscle cells were also followed in their proliferation by DNAsynthesis assay; their adhesion on the substrate was followed as perpreadipocyte cells. Myocytes also showed good proliferation as well asadhesion on the beads.

6.12 Example 12 In vitro Myocyte Adhesion and Growth on Polymeric Beads

In order to assess the ability of polymeric beads from Example 2 toallow adhesion and growth of muscle cells, fresh smooth cell myocyteswere collected from rat esophagus according to classical procedures.Cells were then cultured in the presence of above described microbeadsat a concentration of about 10⁶ cells/ml using the classical protocolfor microcarrier culture in vitro. In a first phase the cells adhered onthe bead surface and then they grow until they cover the total beadsurface. The total colonization period was about 72 hours.

Myocytes from this type of culture showed good growth and behavior anddisplayed the specific myosin marker. These microbeads having cellsadhered thereto are useful for tissue bulking in accordance with thepresent invention. The beads from Examples 2 to 5 can be similarlyassessed.

6.13 Example 13 Preparation of Injectable Suspension of Cell-microbeadParticles for In Vivo Bulking

At the issue of cell culture phase, the cell-bead particles arecollected by filtration and washed extensively with blood serum from thehost where the material is to be implanted. This operation ensures theelimination of foreign material from cell culture. The microbeads arethen suspended in a few ml of autologous serum (a ratio of beads/serumis about 1:1) and are ready to be injected within the tissue to bebulked by means of an appropriate syringe or other injection device.

6.14 Example 14: Preparation of Injectable Suspension of Cell-microbeadsParticles for In Vivo Bulking

Microbeads described in Example 2 are colonized with rat muscle cellsaccording to Example 10 and conditioned according to Example 13 usingrat serum diluted with physiological saline (50%-50%). The final sterilesuspension of cells anchored on beads (50% of volume is constituted ofbeads and 50% of physiological saline) is injected in the right thighmuscle of a rat. Three months after bead injection the muscle wasobserved in its shape and histologically examined. Muscle volume shouldbe larger than the left thigh muscle upon autopsy. Beads inside themuscle mass should appear surrounded by fibroblastic cells with nospecific adverse inflammatory or necrosis effects.

The embodiments of the present invention described above are intended tobe merely exemplary and those skilled in the art will recognize, or beable to ascertain using no more than routine experimentation, numerousequivalents to the specific procedures described herein. All suchequivalents are considered to be within the scope of the presentinvention and are covered by the following claims.

The contents of all references described herein are hereby incorporatedby reference.

Other embodiments are within the following claims.

What is claimed is:
 1. A method for treating urinary incontinence which comprises administering to a mammal in need of such treatment a therapeutically effective amount of biocompatible cationic hydrophilic flexible microparticles comprising a positive charge on their surface, said administration into the bladder sphincter.
 2. The method of claim 1 wherein said mammal is a human.
 3. The method of claim 1 wherein the microparticles are pre-treated with, administered with or coated with autologous cells.
 4. The method of claim 1 wherein the microparticles are washed with serum or whole blood prior to administration.
 5. The method of claim 3 wherein the microparticles are washed with serum or whole blood prior to administration.
 6. The method of claim 3 wherein the autologous cells are bladder cells, muscle cells, fat cells or combinations thereof.
 7. The method of claim 1 wherein the microparticles are coated with or covalently linked to at least one of collagen or a derivative thereof, glucosaminoglycan, or a mixture thereof.
 8. The method of claim 1 wherein the microparticles are administered in a sterile and pyrogen-free injectable solution.
 9. The method of claim 1 wherein said administration is made via syringe.
 10. The method of claim 1 wherein said microparticles are spherical.
 11. The method of claim 10 wherein said microparticles comprise a hydrophilic copolymer which comprises in copolymerized form about 25 to about 99% by weight of neutral hydrophilic acrylic monomer, about 2 to about 50% by weight of one or more monomers having a cationic charge, and about 1 to about 30% by weight of a functionalized monomer.
 12. The method of claim 1 wherein said microparticles are loaded with or administered with one or more anti-inflammatory agents.
 13. The method of claim 11 wherein said microparticles have a diameter ranging between about 10 to about 1000 μm.
 14. A method for treating urinary incontinence disease comprising: (a) preparing cationic flexible microparticles which comprises hydrophilic polymers; (b) administering the resulting microparticles to a mammal through the urethra and injecting the microparticles into walls of the bladder sphincter.
 15. The method of claim 11, wherein the microparticles further comprise a cell adhesion promoter.
 16. The method of claim 11, wherein the microparticles further comprise a cell adhesion promoter.
 17. The method of claim 14, wherein the microparticles further comprise a cell adhesion promoter.
 18. The method of claim 1, wherein the microparticles are administered with a therapeutic agent.
 19. The method of claim 18, wherein the therapeutic agent is selected from the group consisting of antidiuretics, anticholinergics, oxybutynin and vasopressins.
 20. The method of claim 1, wherein the microparticles are administered with one or more of an anti-inflammatory agent, an angiogenesis inhibitor, a radioactive element, and an antimitotic agent.
 21. The method of claim 1, wherein the microspheres further comprise one or more of a therapeutic agent, an anti-inflammatory agent, an angiogenesis inhibitor, a radioactive element, and an antimitotic agent. 